Drug Trial Radar · NCT00667108
A Study of Single-Dose Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance
Last checked: Nov 19, 2026Latest source record: Feb 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
784
Actual
Start
Oct 2004
Primary completion
Not stated
Study completion Jan 2005
Sponsor
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
- Sponsor type
- Industry
- First posted
- Apr 25, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the effect of gabapentin as compared to placebo on sleep, using subjective sleep measurements, in subjects with transient insomnia induced by a sleep phase advance.
Conditions
- Transient Insomnia
Interventions
GabapentinDrug
Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
GabapentinDrug
Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
PlaceboDrug
Matched placebo 30 minutes prior to bedtime
Primary outcomes
What the sponsor says the trial is designed to measure.
- Subjective sleep latencyTime frame: Hour +8
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Pfizer Investigational Site
Anaheim, California
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
Orlando, Florida
Pfizer Investigational Site
Boise, Idaho
Pfizer Investigational Site
Mount Laurel, New Jersey
Pfizer Investigational Site
Cincinnati, Ohio
Pfizer Investigational Site
Spartanburg, South Carolina
Pfizer Investigational Site
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.